Ocumetics Director and CEO, Dean Burns, covers key details of our upcoming first-in-human study and recently opened private placement financing. Topics will include:
- Final steps leading up to the first-in-human study
- Details on the now-open private placement investment opportunity
- Live Q&A session with Dean Burns
Thanks to everyone who joined us for the Webinar. It was an amazing turnout, and it was great to hear your questions and comments. We look forward to hosting more webinars in the future!
https://youtu.be/Ijzsqq2myh4
Ocumetics Director and CEO, Dean Burns, walks through relevant topics including: Manufacturing of the Ocumetics IOL Journey to first-in-human study Q&A session Thanks to everyone who joined us for the Webinar. It was an amazing turnout, and it was great to hear your questions and comments. We look forward to hosting more webinars in the
Dear Ocumetics Team, Partners and Stakeholders, I am thrilled to share an exciting update in our journey to revolutionize vision correction technology. Last week, we proudly announced, in a separate press release, the commencement of manufacturing for the Ocumetics accommodating intraocular lens (IOL). This is not just a milestone for our corporation, but a significant
Ocumetics Announces Completion of First Tranche of Debenture Private Placement for Net Proceeds of CA$2.82 Million Dear Ocumetics Investors, I am thrilled to share some exciting news that marks a significant milestone for our company and our mission to revolutionize eye care technology. I am pleased to announce that Ocumetics has successfully closed the first
Understanding the significance of the biocompatibility journey and why it’s essential for US FDA Approval Earlier this week, Ocumetics sent out a press release announcing that we completed our three-month biocompatibility study and received very favorable results. Receiving favorable results in this study is a critical aspect in the field of health care and medical
